| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(1 year, 3 months from now) | |
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(4 years from now) | |
Edarbi is owned by Azurity.
Edarbi contains Azilsartan Kamedoxomil.
Edarbi has a total of 3 drug patents out of which 0 drug patents have expired.
Edarbi was authorised for market use on 25 February, 2011.
Edarbi is available in tablet;oral dosage forms.
Edarbi can be used as treatment of hypertension.
The generics of Edarbi are possible to be released after 26 March, 2028.
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
Market Authorisation Date: 25 February, 2011
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
EDARBI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic